A Comparison Between Ivor-Lewis and McKeown Minimally Invasive Esophagectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-01

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Surgery is still the main treatment for esophageal cancer, however, the complication and mortality rate of open esophagectomy is high. As a result, the thoracoscopic- laparoscopic minimally invasive esophagectomy (MIE) was developed. The MIE mainly comprised two surgical approaches:

MIE McKeown approach (cervical anastomosis) and MIE Ivor-Lewis approach (intrathoracicanastomosis). The MIE with intrathoracic anastomosis (Ivor-Lewis) is increasingly used for the treatment of mid and lower esophageal cancers. Our study is trying to compare the safety, feasibility, and short-term and long- term outcomes between MIE Ivor-Lewis approach and MIE McKeown approach for the treatment of lower thoracic esophageal cancer and esophageal- gastric junction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Robot-assisted IVOR-LEWIS Esophagectomy

NCT03140189

Clinical or Oncologic Benefits of Robot-assisted IVOR-LEWIS in Esophageal Cancer

UNKNOWN

Minimally Invasive Intrathoracic Esophagogastric Side to Side Anastomosis vs. End to Side Anastomosis

NCT05812495

Epiphora Due to Insufficient Drainage, Left Side Epiphora Due to Insufficient Drainage, Right Side

UNKNOWN NA

Lifting of Gastric Tube Through Trans-substernal Versus Trans-esophageal Bed Path in MIE

NCT02309619

Esophageal Neoplasms Esophagectomy

UNKNOWN NA

A Observational Study to Compare Effectiveness and Safety of the Surgeries in Patients With Esophageal Cancer

NCT03428074

Esophageal Cancer

COMPLETED

Minimally Invasive Esophagectomy (MIE) in Prone Versus Left Decubitus Position

NCT01144325

Esophageal Cancer Esophagectomy

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ivor-Lewis group

minimally invasive esophagectomy (MIE) with intrathoracic anastomosis

Group Type EXPERIMENTAL

MIE Ivor- Lewis

Intervention Type PROCEDURE

minimally invasive esophagectomy (MIE) with intrathoracic anastomosis

McKeown group

minimally invasive esophagectomy (MIE) with cervical anastomosis

Group Type ACTIVE_COMPARATOR

MIE McKeown

Intervention Type PROCEDURE

minimally invasive esophagectomy (MIE) with cervical anastomosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MIE Ivor- Lewis

minimally invasive esophagectomy (MIE) with intrathoracic anastomosis

Intervention Type PROCEDURE

MIE McKeown

minimally invasive esophagectomy (MIE) with cervical anastomosis

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

(I) Patients with clinically staged T1-3N0-2M0 tumors; good cardiopulmonary function;

(II) Patients with lower thoracic esophageal tumors and esophageal- gastric junction tumor;

(III) Patients without a previous history of cancer;

(IV) Patients without a previous history of neck or chest surgery;